Predictors of biochemically or structurally incomplete response for adults with papillary thyroid microcarcinomas included multiple factors such as distant metastases at diagnosis and the use of ...

This high-risk group includes patients with high-grade papillary stage Ta or T1 tumors and any patient with carcinoma in situ (CIS), and makes up 15–44% of patients with non-muscle-invasive ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

The main supervisor is Ivan Shabo. My thesis is about prognostic factors in papillary thyroid cancer, which is the most common type of cancer in the thyroid gland. Today, treatment with surgery ...

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...